The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Attention-Deficit/Hyperactivity Disorder

In brief

The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.

Key facts

Study ID
NCT06115603
Run by
University of Arkansas, Fayetteville
People needed
76
Starts
2024-12-14
Expected to finish
2026-07-01
Last updated by the study team
2026-05-27

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.